Unethical pharmaceutical marketing: a common problem requiring collective responsibility

Shai Mulinari; Piotr Ozieranski

doi:10.1136/bmj-2023-076173

Unethical pharmaceutical marketing: a common problem requiring collective responsibility

Shai Mulinari, Piotr Ozieranski

Lund University

Research output: Contribution to journal › Comment/debate › peer-review

11 Citations (SciVal)

274 Downloads (Pure)

Abstract

Shai Mulinari and Piotr Ozieranski argue healthcare professionals and organisations should respond more forcefully to unethical marketing and support stronger regulatory action

Original language	English
Article number	e076173
Journal	BMJ
Volume	382
Early online date	19 Sept 2023
DOIs	https://doi.org/10.1136/bmj-2023-076173
Publication status	Published - 19 Sept 2023

Bibliographical note

Competing interests: We have read and understood BMJ policy on declaration of interests and declare that SM’s partner is employed by ICON, a global contract research organisation whose customers include many pharmaceutical companies. PO’s former PhD student was supported by a grant from Sigma Pharmaceuticals, which is a UK wholesaler and distributor.

Keywords

Humans
Pharmaceutical Preparations
Marketing

Access to Document

10.1136/bmj-2023-076173

Mulinari_Ozieranski_BMJ_2023Accepted author manuscript, 1.83 MB

Cite this

@article{d42cdca08b1e4cba967c2e997a6ad7a9,

title = "Unethical pharmaceutical marketing: a common problem requiring collective responsibility",

abstract = "Shai Mulinari and Piotr Ozieranski argue healthcare professionals and organisations should respond more forcefully to unethical marketing and support stronger regulatory action",

keywords = "Humans, Pharmaceutical Preparations, Marketing",

author = "Shai Mulinari and Piotr Ozieranski",

note = "Competing interests: We have read and understood BMJ policy on declaration of interests and declare that SM{\textquoteright}s partner is employed by ICON, a global contract research organisation whose customers include many pharmaceutical companies. PO{\textquoteright}s former PhD student was supported by a grant from Sigma Pharmaceuticals, which is a UK wholesaler and distributor.",

year = "2023",

month = sep,

day = "19",

doi = "10.1136/bmj-2023-076173",

language = "English",

volume = "382",

journal = "BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Unethical pharmaceutical marketing

T2 - a common problem requiring collective responsibility

AU - Mulinari, Shai

AU - Ozieranski, Piotr

N1 - Competing interests: We have read and understood BMJ policy on declaration of interests and declare that SM’s partner is employed by ICON, a global contract research organisation whose customers include many pharmaceutical companies. PO’s former PhD student was supported by a grant from Sigma Pharmaceuticals, which is a UK wholesaler and distributor.

PY - 2023/9/19

Y1 - 2023/9/19

N2 - Shai Mulinari and Piotr Ozieranski argue healthcare professionals and organisations should respond more forcefully to unethical marketing and support stronger regulatory action

AB - Shai Mulinari and Piotr Ozieranski argue healthcare professionals and organisations should respond more forcefully to unethical marketing and support stronger regulatory action

KW - Humans

KW - Pharmaceutical Preparations

KW - Marketing

UR - https://www.scopus.com/pages/publications/85171900075

UR - https://www.bmj.com/content/382/bmj-2023-076173.full

U2 - 10.1136/bmj-2023-076173

DO - 10.1136/bmj-2023-076173

M3 - Comment/debate

C2 - 37726130

SN - 0959-8146

VL - 382

JO - BMJ

JF - BMJ

M1 - e076173

ER -

Unethical pharmaceutical marketing: a common problem requiring collective responsibility

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations

What can be learnt from the new pharmaceutical industry payment disclosures?

Cite this

Unethical pharmaceutical marketing: a common problem requiring collective responsibility

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Projects

Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations

What can be learnt from the new pharmaceutical industry payment disclosures?

Cite this